<DOC>
	<DOCNO>NCT01000727</DOCNO>
	<brief_summary>This study test whether darapladib safely low chance cardiovascular event ( heart attack urgent coronary revascularization ( e.g . medical procedure perform restore normal blood flow patient atherosclerosis ) ) treatment start within 30 day acute coronary syndrome ( also call ACS ) .</brief_summary>
	<brief_title>The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial</brief_title>
	<detailed_description>Subjects qualify study randomized 1:1 either darapladib placebo administer addition standard therapy . Following baseline visit , subject expect return clinic visit 1 month , 3 month , 6 month every 6 month end study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Signed write informed consent . Men woman least 18 year old ( Taiwan , least 20 year old ) . Women must postmenopausal use highly effective method avoidance pregnancy . Hospitalization acute coronary syndrome ( ACS ) within 30 day prior study entry . Clinically stable 24 hour prior study entry . A planned percutaneous coronary intervention ( PCI ) perform prior study entry , whenever possible . At least one following : At least 60 year old . Myocardial infarction prior qualify ACS event . Diabetes mellitus require treatment medication . Diagnosed mild moderate reduction kidney function . Cerebrovascular disease ( carotid artery disease ischemic stroke 3 month prior study entry ) OR peripheral artery disease . ACS symptom lab result believe caused narrowing block coronary artery . No major coronary artery blockage 50 % ( unless stenosis successfully treat PCI ) . Planned coronary artery bypass graft ( CABG ) surgery , CABG surgery perform qualify ACS event prior study entry . Certain type liver disease . Severe reduction kidney function OR removal kidney OR kidney transplant . Severe heart failure . Blood pressure high normal despite lifestyle change treatment medication . Any lifethreatening disease life expectancy le 2 year ( heart disease ) may prevent subject complete study . Severe asthma poorly control medication . Pregnancy ( Note : A pregnancy test perform nonsterile woman prior study entry ) . Previous severe allergic reaction food , medication , drink , insect sting , etc . Drug alcohol abuse within past 6 month . Mental/psychological impairment may prevent subject comply study procedure understand goal potential risk participate study . Certain medication may interfere study medication ( identify study doctor ) . If birth parent least 50 % Japanese , Chinese , Korean ancestry , must blood sample collected LpPLA2 activity . Those LpPLA2 activity less equal 20.0 nmol/min/mL exclude . Previously take darapladib ( SB480848 ) . Participation study investigational medication within past 30 day . Current participation study investigational device . Any reason investigator deems subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atherosclerosis</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Lp-PLA2 inhibitor</keyword>
	<keyword>The TIMI Study Group</keyword>
	<keyword>Coronary Heart Disease ( CHD )</keyword>
	<keyword>Acute Coronary Syndrome ( ACS )</keyword>
</DOC>